Bollinger Ingham's live swine fever vaccine product developed in China approved

Introduction: Bollinger Ingehan announced that its localresearch in China's swine fever live vaccine (C strain, PK/WRL cell source) has been issued by the Ministry of Agriculture and Rural Affairs of China", the first in the Chinese market by multinational enterprises and domestic research institutes jointly developed swine fever live vaccine products
Bollinger Ingham announced Its localresearch and development of live swine fever vaccine (C strain, PK/WRL cell source) (English product name: Ingelvac® CSFMLV) was awarded by the Ministry of Agriculture and Rural Affairs of China's "New Veterinary Medicine Registration Certificate", becoming the first in the Chinese market by multinational enterprises and domestic research institutes jointly developed swine fever live vaccine productsThis marks another milestone in Bollinger Ingham's "Rooting in China, Serving China", which aims to provide innovative, high-quality pig vaccines and more comprehensive pig farm disease solutions for the Chinese pig industrySwine fever is a highly contact, deadly infectious disease in pigs caused by the Classical Swine Fever Virus (CSFV)Because of the high degree of harm caused by the disease, the economic loss to the pig industry is huge, china has designated it as a kind of animal diseaseAt present, the prevention of CSF is mainly based on the live vaccine to prevent swine fever, effectively controlling the outbreak of CSF, butthe disease still exists endemic epidemic and dot-based distributionmost live swine fever vaccines currently available on the market can only be kept at -15 degrees Celsius for 18 months, and the cold chain transport, preservation and dilution of the vaccine have strict temperature requirementsAndthe approved swine fever live vaccine using advanced microcarrier suspension culture technology and freeze-dried protection technology, to ensure that the virus harvest drops high, vaccine production process is stable, the quality is controlled, can be preserved at 2-8 degrees Celsius for 24 monthsthis product will bring high-quality products to China's pig industry, break through the traditional immunization program and its supporting disease solutions, but alsowill promote China's swine fever purification cause to successthe live swine fever vaccine, which will be produced at the Bollinger Ingerheimtai plant, is expected to be officially commercialized in early 2021, making it the first pig vaccine product to be developed and produced in China from development to productionIt will also be another heavyweight product supplied by the Taizhou plant following the Lanfaule ®, a live vaccine for pig breeding and respiratory syndromeimportant milestones of the swine fever live vaccine (C strain, PK/WRL cell source)swine fever live vaccine (C strain, PK/WRL transmission cell source)In 2012, Bollinger Ingerheim established an Asian Animal Health Research and Development Center in China to launch a swine fever vaccine research and development project 2014, PK/WRL cell was introduced from Bollinger Ingham Animal Health (USA) Co., Ltd and successfully domesticated the C strain in the cell, screening for high-droplet strains In 2015, high-density suspension culture technology based on microcarriers and stable freeze-dried protection processes were successfully developed In 2016, laboratory safety tests, efficacy tests and stability tests were completed, and pilot products were successfully produced and clinical trials applied for research 2017, successfully completed clinical trials On June 10, 2020, it obtained the Certificate of Registration of New Veterinary Medicineapproved by the Ministry of Agriculture and Rural Affairs of China Source: Bollinger Ingham (sic)